In these studies, natalizumab was capable of overcoming stroma-mediated drug resistance to rituximab in a panel of B-lymphoma cell lines [186] and also decreased CLL migration in a physiologically relevant model of lymphocyte migration [187], demonstrating that direct targeting of CD49d may have therapeutic implications in CLL. The gene discussed is ITGA4; the disease is B-cell chronic lymphocytic leukemia.